You can't judge a peptide by how it looks. Verification is documentation-based, and it rests on two lab tests: mass spectrometry (is it the right molecule?) and HPLC (how pure is it?). A credible Certificate of Analysis shows both, is tied to a specific batch/lot number, comes from an independent accredited lab, and is published openly — not emailed on request.
Even a perfect COA has limits: it describes a tested sample, not necessarily the exact vial in your hand, and it says nothing about sterility. Independent third-party testing of the actual lot is the strongest signal — and recent testing has caught products, including some sold as retatrutide, failing badly.
The honest bottom line: outside an FDA-approved medicine prescribed by a clinician, identity, dose accuracy, and sterility cannot be fully guaranteed. This page explains how to read the evidence and weigh the risk — it does not endorse buying or using unapproved compounds.
→ Score a specific seller against 20 criteria with our Vendor Evaluation Checklist.
Why this matters now
For years, "research use only" peptides were sold openly online with little oversight. That era is ending. Across 2025 and into 2026, federal enforcement escalated from paperwork to physical action, and the market's biggest names disappeared — taking customers' pending orders and store credit with them.
A compressed timeline of what changed:
| When | What happened |
|---|---|
| Late 2023 | FDA moved a list of widely used peptides to its "Category 2" — effectively blocking compounding pharmacies from preparing them. |
| Dec 2024 | FDA issued warning letters to several named research-peptide vendors for selling unapproved drug products. |
| Feb 2025 | FDA declared the semaglutide shortage resolved, closing the compounding loophole that had allowed mass GLP-1 production. |
| June 2025 | Federal agents raided the Amino Asylum warehouse — the first physical raid on a major vendor, who went offline within days. |
| Sept 2025 | The FDA sent 50+ warning letters to peptide vendors and GLP-1 compounders in a single month. |
| Dec 2025 | Founders of Paradigm Peptides pleaded guilty to federal charges after products labeled as SARMs were found to contain testosterone, a controlled substance. |
| March 2026 | Peptide Sciences — the largest grey-market vendor, doing an estimated $7.4M/month — abruptly shut down with a brief notice, no refunds, no forwarding address. |
At least seven other research-peptide companies closed during 2025, and an earlier DOJ prosecution (Tailor Made Compounding) ended in a $1.79 million forfeiture for distributing unapproved peptides. The takeaway for anyone trying to evaluate this market: vendors can vanish overnight, and a polished website is not evidence of a quality product. For the regulatory specifics, see our news coverage of the 503B bulks-list proposal and the Category 2 peptide changes, plus our explainer on whether peptides are legal.
The two tests that actually matter
Almost everything in peptide verification reduces to two analytical methods. Knowing what each one proves — and what it doesn't — is most of the battle.
| Test | Question it answers | What it reports |
|---|---|---|
| Mass spectrometry (MS) | Is it the right molecule? (Identity) | The measured molecular mass; it should match the target compound's expected mass. |
| HPLC (high-performance liquid chromatography) | How pure is it? (Purity) | A purity percentage — how much of the sample is the target vs impurities (e.g., 98.7%). |
The two are complementary, not interchangeable. Mass spec can confirm the right molecule is present while saying little about how much junk rides along with it; HPLC can show a high purity figure for whatever the main component is — but if you never confirmed identity, a high-purity number is meaningless. A trustworthy COA shows both. A report with only one test, or with no methods listed at all, is incomplete by definition.
You'll occasionally see additional assays — endotoxin testing (for bacterial contamination), water/moisture content, or appearance — which are useful extras, but identity and purity are the non-negotiable core.
How to read a Certificate of Analysis
A COA is just a lab report for a specific batch of material. Here's the anatomy of a credible one, field by field:
- Compound name & stated specification — what it claims to be, and the target purity it's measured against.
- Batch / lot number — this should match the lot printed on the vial you received. A COA for a different lot tells you nothing about your product.
- Test date — recent and tied to that lot, not a generic report from many months ago.
- Methods — both HPLC and mass spec should be named.
- Purity result — an actual number with the chromatogram, not just the word "passed."
- Identity result — the measured mass matching the expected molecular weight.
- Testing lab & accreditation — the name of an independent lab, ideally with accreditation (for example, ISO/IEC 17025), not "tested in-house."
Use this quick contrast when you're looking at one:
| Signal | Stronger COA | Weaker COA |
|---|---|---|
| Who tested it | Named independent accredited lab | "In-house," unnamed, or no lab listed |
| Batch match | Lot number matches your vial | Generic / mismatched / no lot |
| Tests shown | HPLC + mass spec, with data | One test, or "passed" with no data |
| Access | Published openly on the site | Only sent if you email and ask |
| Recency | Recent, dated, lot-specific | Old or undated |
Independent vs in-house testing
The single most important COA signal is who ran the test. A vendor that certifies its own purity is grading its own homework — there's no independent check on the result, and no accountability if it's wrong. Independent, accredited third-party laboratories exist specifically to provide that check, and reputable analytical labs in this space (such as Janoshik Analytical, among others) publish testing that buyers and communities can scrutinize.
This isn't theoretical. Independent testing has repeatedly flagged grey-market products that failed identity or purity expectations — including batches sold as popular compounds like CJC-1295, tesamorelin, and retatrutide receiving failing grades. In other words, third-party testing works precisely because it sometimes catches products that the seller's own marketing would never admit to. When a vendor points to recent, independent, lot-specific results that anyone can read, that's the strongest signal available. When testing is buried, vague, or self-reported, treat the claims with skepticism. (For the compound at the center of much of this scrutiny, see the Retatrutide hub.)
Red flags & how to spot a misrepresented product
No single red flag is proof of a bad actor, but they stack. Be wary when you see:
- Hype in place of data. "Premium," "pharmaceutical grade," "99%+ guaranteed" with no published COA to back it. When claims scale up while evidence scales down, trust should move the opposite way.
- COAs you can't get without asking. If documentation is real, it's usually published. Email-only COAs are a yellow flag.
- Generic or mismatched batch numbers. A COA that doesn't correspond to your actual lot is decorative, not evidential.
- Self-certification only. No named third-party lab anywhere.
- Human-use marketing on a "research only" product. Dosing-for-people language, brand-name impersonation, or "how to inject" guidance alongside a research-only disclaimer is a contradiction regulators have been prosecuting.
- Prescription drugs sold next to research chemicals. A catalog mixing controlled or prescription-only items with peptides signals a willingness to cross legal lines.
- Prices far below everyone else. Underpricing the market is often subsidized by skipping testing, identity, or sterility.
- No business identity. No address, no accountable entity, payment pushed to hard-to-reverse methods.
→ Turn these into a structured score for any specific seller with the Vendor Evaluation Checklist (20 criteria), and read the deeper walkthrough in How to Evaluate a Peptide Vendor.
What you can — and can't — verify as a buyer
It's important to be honest about the ceiling here. A COA, even a good one, has real limits:
- It describes a sample, not your vial. A report shows what a lab measured in a tested portion of a batch. It is strong evidence, but it is not a guarantee that the specific unit you received is identical.
- It usually doesn't address sterility. Purity is not the same as sterile, endotoxin-free, or safe to introduce into a body.
- It can be forged. A PDF is easy to fake; independent, openly published, lot-matched results from a named lab are much harder to fabricate convincingly.
- It says nothing about long-term safety or correct use. Many of these compounds are investigational, with unknown long-term profiles.
Which leads to the one claim this page will make plainly: the only path where identity, dose, and sterility are actually guaranteed is an FDA-approved medicine dispensed through a licensed clinician and pharmacy. Everything in the grey market is a spectrum of risk that documentation can narrow but never eliminate. Grey Peptides exists to help you read that documentation accurately and understand the landscape — not to sell you a product or send you to one.
Frequently asked questions
What does a COA actually prove?
That a lab tested a batch and got certain identity and purity results. A strong COA — independent, accredited, lot-matched, both tests shown — is the best documentary evidence available, but it characterizes a sample, not necessarily your exact vial, and it doesn't certify sterility.
Is HPLC or mass spec more important?
Neither alone is enough. Mass spec proves identity; HPLC proves purity. A purity percentage is meaningless if you never confirmed the molecule's identity, and a confirmed identity tells you nothing about contaminants. Insist on both.
Can a Certificate of Analysis be fake?
Yes. PDFs are trivial to alter. That's why independent, openly published, lot-specific results from a named accredited lab carry far more weight than a document a seller emails you on request.
Does third-party testing make a peptide safe?
No. It can raise confidence in identity and purity, but it doesn't address sterility, correct dosing, or long-term safety — and many of these compounds are investigational. "Verified pure" is not "verified safe."
Why doesn't Grey Peptides recommend a vendor?
Because the moment a site earns commissions from sellers, its "recommendations" stop being neutral. We sell nothing and link to no vendors, so the only thing we have to offer is accurate information. That's the point.
Related on Grey Peptides
Tools & guides
From the News Wire
FDA proposes ending mass GLP-1 compounding → FDA pulls 12 peptides off its "do not compound" list →Get verification updates
We track enforcement actions, lab-testing developments, and regulatory changes as they land. No spam, unsubscribe anytime.
Sources
Enforcement actions are drawn from FDA announcements, DOJ/US Attorney filings, and contemporaneous trade reporting; analytical-method descriptions reflect standard laboratory practice.
- U.S. FDA — warning letters and bulks-list (503A/503B, Category 2) determinations affecting peptides, 2023–2026.
- U.S. Department of Justice / U.S. Attorney filings — peptide and compounding prosecutions (e.g., Tailor Made Compounding forfeiture; Paradigm Peptides guilty pleas, 2025).
- Contemporaneous trade and legal reporting on the June 2025 Amino Asylum raid and the March 2026 Peptide Sciences closure.
- Independent analytical laboratories (e.g., Janoshik Analytical) — third-party identity/purity testing of grey-market peptide products.
- Standard references for HPLC (purity) and mass spectrometry (identity) in peptide characterization.
Educational only — not medical or legal advice, and not an endorsement of buying or using any unapproved compound. The only verified-safe path to a peptide medicine is an FDA-approved product prescribed by a licensed clinician.